Investor List:

Top Diagnostics Series A Investors in Boston / New England (53)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Diagnostics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Manufacturing (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Cris De Luca, Partner at Sanofi Ventures
Cris De Luca
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Paris (France), Investors in Israel, Investors in New York (NY), Investors in Europe, Investors in San Francisco (CA), Investors in Cambridge (MA)
Investors in AR/VR (Series A), Investors in AR/VR (Series B), Investors in Consumer Health (Series B), Investors in AI (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in IoT (Series B), Investors in Medical Devices (Series A), Investors in IoT (Series A), Investors in Pharmaceuticals (Series B), Investors in Diverse Investors (Other Lists), Investors in Pharmaceuticals (Series A), Investors in Investors who were founders (Other Lists), Investors in Health IT (Series A), Investors in Investors who invested in female founders (Other Lists), Investors in Israel (Other Lists), Investors in AI (Series A), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists), Investors in AR/VR (Series A), Investors in AR/VR (Series A), Investors in AI (Series A), Investors in AI (Series A), Investors in AR/VR (Series A), Investors in AI (Series A), Investors in AR/VR (Series A), Investors in Consumer Health (Series A), Investors in Consumer Health (Series A), Investors in Consumer Health (Series A), Investors in AI (Series A), Investors in Consumer Health (Series A), Investors in IoT (Series A), Investors in IoT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in IoT (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in IoT (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Series A), Investors in AR/VR (Series B), Investors in Pharmaceuticals (Series A), Investors in AI (Series B), Investors in AR/VR (Series B), Investors in Pharmaceuticals (Series A), Investors in AI (Series B), Investors in Consumer Health (Series B), Investors in Consumer Health (Series B), Investors in AI (Series B), Investors in Consumer Health (Series B), Investors in AR/VR (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in AI (Series B), Investors in AR/VR (Series B), Investors in IoT (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in IoT (Series B), Investors in IoT (Series B), Investors in IoT (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series A)
Photo of Jorge Cortell, General Partner at Unveil Pharma
Jorge Cortell
Unveil Pharma·General Partner
Sweet spot: $1.5M
Range: $500K - $20.0M
Investors in Cambridge (MA), Investors in Boston (MA), Investors in Singapore
Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Seed), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in Investors who invested in diverse founders (Other Lists), Investors in Medical Devices (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Series A), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who were founders (Other Lists), Investors in BioTech (Series A), Investors in Diverse Investors (Other Lists), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Medical Devices (Pre-seed), Investors in Health & Hospital Services (Seed), Investors in Drug Delivery (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series A), Investors in Medical Devices (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Series A), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Drug Delivery (Seed), Investors in Digital Health (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Health IT (Pre-seed), Investors in Health IT (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Pre-seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series A), Investors in Drug Delivery (Pre-seed), Investors in Health IT (Seed), Investors in Medical Devices (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed)
Photo of Jon Lim, Partner at F-Prime Capital Partners
Jon Lim
Sweet spot: $5.0M
Range: $100K - $10.0M
Investors in Boston (MA)
Photo of Andrew Hack, Managing Director at Bain Capital Life Sciences
Andrew Hack
Bain Capital Life Sciences·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed)
Photo of Walter Gilbert, Managing Partner at BioVentures Investors
Walter Gilbert
BioVentures Investors·Managing Partner
Sweet spot: $10.0M
Range: $5.0M - $25.0M
Investors in Cambridge (MA)
Photo of Jennifer Levin Carter, Managing Director at Sandbox Industries
Jennifer Levin Carter
Sandbox Industries·Managing Director
Sweet spot: $10.5M
Range: $1M - $20.0M
Investors in Boston (MA)
Investors in AI (Series B), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in AI (Seed), Investors in Health IT (Series A), Investors in AI (Seed), Investors in Health & Hospital Services (Series B), Investors in AI (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in AI (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in AI (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
KK
Kelvin Keh
Covalent Ventures·Managing Partner
Sweet spot: $2.0M
Range: $500K - $4.0M
Investors in Thailand, Investors in Indonesia, Investors in Boston (MA), Investors in San Francisco (CA), Investors in Singapore, Investors in Sydney (Australia), Investors in Melbourne (Australia), Investors in New Zealand
Investors in Food and Beverage (Series A), Investors in Impact (Series A), Investors in Medical Devices (Series A), Investors in Diverse Investors (Other Lists), Investors in Health IT (Series A), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Food and Beverage (Series A), Investors in Impact (Series A), Investors in Health IT (Series A), Investors in Impact (Series A), Investors in Food and Beverage (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Boston / New England (Other Lists), Investors in Drug Delivery (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Drug Delivery (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Series A), Investors in Digital Health (Series A)